|[January 02, 2013]
Foundation Medicine to Present at the 31st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(Business Wire)--
Medicine, Inc., a molecular information company that brings
comprehensive cancer genomic analysis to routine clinical care, today
announced that Michael J. Pellini, M.D., president and chief executive
officer, will present an overview of the company at the 31st
Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel
in San Francisco on Wednesday, January 9, 2013 at 7:30 a.m. PT.
Dr. Pellini will provide an update on the recent commercial launch of
Foundation Medicine's first clinical product, FoundationOne™,
a pan-cancer, fully informative genomic profile designed to help
oncologists expand their patients' treatment options.
is a fully informative genomic profile that cmplements traditional
cancer decision tools and often expands treatment options by matching
each patient with targeted therapies that may be relevant to the
molecular changes in their tumor. Using next-generation sequencing,
FoundationOne interrogates all genes somatically altered in human
cancers that are validated targets for therapy or unambiguous drivers of
oncogenesis based on current knowledge. It reveals all classes of
genomic alterations including base substitutions, insertions, deletions,
copy number alterations and select rearrangements. Each patient's
genomic profile is reported to the physician matched with targeted
therapies and clinical trials that may be relevant based on the
molecular blueprint of their tumor. Results are supported by the latest
scientific and medical evidence. FoundationOne has been optimized to fit
easily into the clinical workflow of a practicing oncologist. It is
available for all solid tumors and clinical grade results can be
obtained from as little as 50ng of DNA obtained from formalin-fixed,
paraffin-embedded tumor tissue samples. FoundationOne is a
laboratory-developed test performed at Foundation Medicine's
CLIA-certified facility and is currently available for all solid tumor
types. Please visit www.foundationone.com
for more information.
About Foundation Medicine
Medicine is a molecular information company dedicated to a
transformation in cancer care in which treatment is informed by a deep
understanding of the genomic changes that contribute to each patient's
unique cancer. The company's initial clinical assay, FoundationOneTM,
is a fully informative genomic profile to identify a patient's
individual molecular alterations and match them with relevant targeted
therapies and clinical trials. Foundation Medicine's molecular
information platform aims to improve day-to-day care for patients by
serving the needs of clinicians, academic researchers and drug
developers to help advance the science of molecular medicine in cancer.
For more information, please visit www.foundationmedicine.com.
Foundation Medicine® is a registered trademark, and FoundationOneTM
is a trademark of Foundation Medicine, Inc.
[ Back To IBM News 's Homepage ]